Squamous cell carcinoma of the lung accounts for approximately 25-30% of all lung cancers and has the strongest association with smoking. It is typically centrally located, originating from proximal bronchi. It shows an endobronchial growth pattern and frequently causes post-obstructive atelectasis/pneumonia. Cavitation rate is the highest among all lung cancer types (30-80%). It can also present as a Pancoast tumor (superior sulcus tumor). Chest wall and mediastinal invasion are common in locally advanced disease.
Age Range
50-80
Peak Age
65
Gender
Male predominant
Prevalence
Common
Squamous cell carcinoma develops from the sequence of squamous metaplasia → dysplasia → carcinoma in situ → invasive carcinoma caused by chronic cigarette smoke exposure in the bronchial epithelium. Because it originates from proximal bronchi, it forms an endobronchial mass and obstructs the bronchial lumen — this is the mechanism of post-obstructive atelectasis and pneumonia. The tumor has a high tendency for central necrosis because rapid growth outpaces blood supply and ischemic necrosis develops — this appears as cavitation on CT. The cavity wall is thick and irregular because it consists of viable tumor tissue. The tumor's keratin production is its histological distinguishing feature and may manifest as high-density areas on CT.
The combination of a thick-walled cavitating mass in the central/hilar region with distal post-obstructive atelectasis/pneumonia is the signature finding of squamous cell carcinoma. On contrast-enhanced CT, the tumor mass is distinguished from atelectatic lung by its heterogeneous enhancement pattern. This finding combination, especially in male patients with heavy smoking history, suggests squamous cell carcinoma with high confidence.
Central/hilar mass: Large mass originating from proximal bronchus, encasing or displacing hilar structures. Typically 3-10 cm in size. Infiltrates the bronchial wall and narrows/obstructs the bronchial lumen. Invasion into mediastinal structures (esophagus, great vessels, trachea) may develop.
Report Sentence
A ___ cm centrally located mass in the right/left hilum is identified, obstructing the main/lobar bronchus and causing distal atelectasis/consolidation; primary squamous cell carcinoma should be the primary consideration.
Cavitation: Thick-walled (>15 mm) cavity with irregular inner surface and eccentric thickening. Cavity wall consists of viable tumor tissue. Air-fluid level may be visible within the cavity. Wall thickness >15 mm indicates malignancy probability >95%. Cavitation rate of 30-80% is the highest among all lung cancers.
Report Sentence
The mass demonstrates thick-walled (wall thickness ___ mm) cavitation with irregular inner surface and eccentric wall thickening consistent with malignancy (squamous cell carcinoma).
Post-obstructive atelectasis/pneumonia: Volume loss and consolidation in the lung segment or lobe distal to the bronchus obstructed by the tumor. Atelectatic lung enhances homogeneously while the tumor mass enhances heterogeneously — this difference allows their differentiation. Persistent/recurrent pneumonia in the same location should raise suspicion for endobronchial lesion.
Report Sentence
Post-obstructive atelectasis/consolidation is identified in the ___ lobe distal to the central mass, with the tumor mass distinguished from atelectatic lung by its heterogeneous enhancement pattern on contrast-enhanced CT.
Pancoast tumor (superior sulcus tumor): Mass at the lung apex with invasion of the brachial plexus, subclavian vessels, first and second ribs, and vertebral bodies. Presents with Horner syndrome (miosis, ptosis, anhidrosis) and arm pain/weakness. Squamous cell carcinoma is the most common Pancoast tumor histology.
Report Sentence
A ___ cm mass at the right/left lung apex is identified, filling the superior sulcus with invasion of adjacent ribs/vertebra/brachial plexus; consistent with Pancoast tumor (squamous cell carcinoma).
Intense FDG uptake on PET-CT: SUVmax typically >5, often ranging 10-25. Squamous cell carcinoma demonstrates the highest FDG uptake among all NSCLC types. Intense uptake in the cavity wall, absence of uptake within the cavity (necrotic area). Critical for mediastinal/hilar lymph node metastasis and distant metastasis staging.
Report Sentence
The central mass demonstrates very intense FDG uptake on PET-CT (SUVmax: ___); marked metabolic activity is seen in the cavity wall while no uptake is present in the intracavitary necrotic area.
Intermediate-low signal intensity on T2-weighted MRI. Keratinization areas may show low T2 signal. Necrotic cavity areas show high T2 signal. MRI is superior to CT for evaluating chest wall, mediastinal, and vertebral invasion.
Report Sentence
The mass demonstrates heterogeneous signal on T2-weighted MRI with intermediate-low signal in solid areas and high signal in necrotic/cavitary areas.
Mediastinal invasion: Central mass invading mediastinal structures (esophagus, trachea, main pulmonary artery, SVC, aorta, recurrent laryngeal nerve). Loss of fat plane between tumor and mediastinal structure favors invasion. SVC invasion may cause SVC syndrome (facial/neck edema, venous distension).
Report Sentence
The central mass is in broad contact with mediastinal structures (___) with loss of the intervening fat plane; mediastinal invasion should be considered.
Criteria
Prominent keratinization (keratin pearls) and intercellular bridges. Most common subtype.
Distinct Features
High cavitation rate, prominent central necrosis. Keratinized areas may show high density on CT. Intermediate prognosis.
Criteria
No keratinization, squamous differentiation confirmed by immunohistochemistry (p40, p63 positive).
Distinct Features
May be morphologically difficult to distinguish from adenocarcinoma — requires immunohistochemistry. No significant imaging difference from keratinizing type but slightly lower cavitation rate.
Criteria
Basaloid cell morphology, high mitosis, comedoid necrosis. Aggressive biology.
Distinct Features
Subtype with worst prognosis. Rapid growth, early metastasis. Large necrotic mass on CT, prominent mediastinal lymphadenopathy. Very high FDG uptake on PET-CT.
Criteria
Located at lung apex with brachial plexus/subclavian vessel/rib invasion. Histologically squamous cell carcinoma most common.
Distinct Features
Clinical: Horner syndrome, arm pain/weakness. MRI superior to CT (brachial plexus/spinal canal evaluation). Neoadjuvant chemoradiation + surgery is standard approach.
Distinguishing Feature
Adenocarcinoma is peripheral, characterized by ground-glass component and spiculated margins. Cavitation is rare (5-10%). Squamous cell carcinoma is central, cavitary, and shows endobronchial growth.
Distinguishing Feature
Small cell carcinoma presents with large hilar/mediastinal mass + massive lymphadenopathy, cavitation is very rare. Rapid growth and early widespread metastasis. Squamous cell carcinoma has frequent cavitation and less massive lymphadenopathy.
Distinguishing Feature
Lung abscess has smooth inner surface with thin wall (<5 mm), air-fluid level, surrounding consolidation. Clinical: fever, cough, sputum. Squamous cell carcinoma has thick wall (>15 mm), irregular inner surface, eccentric thickening.
Distinguishing Feature
Tuberculoma is typically in upper lobe apical/posterior segment, smooth or lobulated margins, frequent central calcification, satellite nodules. Cavitation is thin-walled. FDG uptake on PET-CT is variable (active TB may have high uptake — pitfall). Squamous cell carcinoma has thick-walled cavitation and calcification is rare.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralSurgical resection (lobectomy/pneumonectomy) is curative in early-stage (I-II) squamous cell carcinoma. Neoadjuvant chemoradiation + surgery is the standard approach for Pancoast tumors. Concurrent chemoradiation ± surgery is used for locally advanced (stage III) disease. Platinum-based chemotherapy + immunotherapy (pembrolizumab — based on PD-L1 expression) is standard for advanced (stage IV) disease. Targeted therapy options are more limited than adenocarcinoma (EGFR/ALK mutations rare). Multidisciplinary tumor board evaluation is required. Bronchoscopy is used for both diagnosis and endobronchial treatment (laser, stent).
Treatment depends on stage: surgery for early stage, chemoradiation and immunotherapy for advanced stage. PD-L1 expression determines immunotherapy response. Cavitation may increase treatment complications.